Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27640500 | 0.78 | SMN1; SMN2 (0.46) | ALDH1A1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL23199385 | 0.73 | MAPT (0.45) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL8587397 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL9519331 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL9363980 | 0.72 | SMN1; SMN2 (0.52) | ALDH1A1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL10639160 | 0.72 | SMN1; SMN2 (0.47) | ALDH1A1MAPTLMNASMN1; SMN2HTR2A | |
| SCHEMBL14188141 | 0.72 | HTT (0.55) | SMN1; SMN2HTTKMT2A | |
| SCHEMBL27501012 | 0.71 | HTT (0.45) | ALDH1A1MAPK1L3MBTL1MAPTLMNA | |
| SCHEMBL27484676 | 0.71 | MAPT (0.61) | ALDH1A1MAPTLMNASMN1; SMN2GAA | |
| SCHEMBL23199272 | 0.71 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNASMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485647-B2 | 2-aminoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MSD K.K. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1630162-A1 | 2-AMINOQUINOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MCHR2, MC2R, MCHR1 | ALDH1A1 1932/4885MAPK1 2151/4885L3MBTL1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.